{"entity":{"id":"darovasertib","kind":"drug","name":"Darovasertib","aka":["IDE 196"],"tldr":"Darovasertib is an experimental small-molecule drug from IDEAYA Biosciences in phase 3 trials for uveal melanoma and melanoma, with its target not yet stated publicly.","summary":"Darovasertib (IDE196, LXS196) is a small-molecule drug developed by IDEAYA Biosciences. The sponsor describes its target as PKC (protein kinase C), which OnCo does not yet have a target page for. The sponsor states: Darovasertib is a small-molecule PKC inhibitor targeting the oncogenic driver of uveal melanoma associated with GNAQ/GNA11 mutations or PRKC fusions. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07804186 (Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma) and NCT07015190 (Neoadjuvant Darovasertib in Primary Uveal Melanoma), in uveal melanoma and melanoma. The largest, NCT07015190, plans to enrol 520 participants with primary completion expected 2030-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Darovasertib","url":"https://clinicaltrials.gov/search?intr=IDE196"},{"label":"Sponsor pipeline page","url":"https://ideayabio.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ideaya-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07804186","nct07015190","nct05987332","nct03947385","nct05907954"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"IDE196, LXS196","modality":"small molecule","mechanism":"Darovasertib is a small-molecule PKC inhibitor targeting the oncogenic driver of uveal melanoma associated with GNAQ/GNA11 mutations or PRKC fusions.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/darovasertib/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"company":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"}],"trial":[{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/"},{"id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/"},{"id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/"},{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/"},{"id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/"}],"target":[{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/"},{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/"}]}}